Table 1

Life expectancy gains from cancer prevention strategies for BRCA1/2 positive women

Author and year

Mutation type

Type of prophylactic intervention

vs. surveillance

Life expectancy gain

(year)


Sonnenberg

et al 1993

BRCA 1/2

Tamoxifen for 5 years

1.6 to 2.2

Schrag

et al 1997

BRCA1/2

Bilateral Mastectomy

Bilateral oophorectomy

2.9 to 5.3

0.3 to 1.7

Grann

et al 1998

BRCA1/2

Bilateral oophorectomy

Bilateral mastectomy

Bilateral mastectomy and oophorectomy

0.4 to 2.6

2.8 to 3.4

3.3 to 6.0

Grann

et al 2000

BRCA1/2

Bilateral oophorectomy

Bilateral mastectomy

Bilateral oophorectomy and mastectomy

Chemoprevention with tamoxifen

Chemoprevention with raloxifene

0.9 ( 95% CI: 0.4-1.2)

3.4 (95% CI: 2.7-3.7)

4.3 (95% CI: 3.6-4.6 )

1.6 (95% CI: 1.0-2.1)

2.2 (95% CI: 1.3-2.8 )

Schrag

et al 2000

BRCA1/2

Tamoxifen for 5 years

Bilateral oophorectomy

Contra-lateral mastectomy

0.4 to 1.3

0.2 to 1.8

0.6 to 2.1

van Roosmalen

et al 2002

BRCA1/2

Bilateral mastectomy and oophorectomy

Breast screening and bilateral oophorectomy

Bilateral mastectomy with ovarian screening

High risk: 11.7. Medium risk 6.6

High risk: 9.5. Medium risk 5.3

High risk: 4.9. Medium risk 4.4

Armstrong

et al 2004

BRCA1/2

Bilateral oophorectomy

Bilateral mastectomy and prophylactic oophorectomy

3.34 to 4.65

5.49 to 7.63


Salhab et al. BMC Women's Health 2010 10:28   doi:10.1186/1472-6874-10-28

Open Data